High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma

Background & Aims: We elucidated the clinical and immunologic implications of serum IL-6 levels in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (Ate/Bev). Methods: We prospectively enrolled 165 patients with unresectable HCC (discovery c...

Full description

Bibliographic Details
Main Authors: Hannah Yang, Beodeul Kang, Yeonjung Ha, Sung Hwan Lee, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Gwangil Kim, Sanghoon Jung, Sun Young Rha, Vincent E. Gaillard, Jaekyung Cheon, Chan Kim, Hong Jae Chon
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:JHEP Reports
Subjects:
Hepatocellular carcinoma
IL-6
Atezolizumab
Bevacizumab
Immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555923000034

Internet

http://www.sciencedirect.com/science/article/pii/S2589555923000034

Similar Items